Patents by Inventor Leo Rubin

Leo Rubin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170189573
    Abstract: Disclosed herein is a novel hemostatic patch that may be used to control and/or arrest bleeding in patients. The patch offers an effective but also minimally invasive way to control and/or arrest bleeding in a patient. The patch comprises a mucoadhesive and a compound that causes vasoconstriction. In a preferred aspect, the patch comprises chitosan and Neuropeptide Y. Also disclosed are methods of using the novel hemostatic patch.
    Type: Application
    Filed: January 12, 2017
    Publication date: July 6, 2017
    Inventors: Leo RUBIN, Shaker MOUSA
  • Publication number: 20170049710
    Abstract: Nanoparticles comprising VIP and their use in treating, e.g., pulmonary hypertension. Such nanoparticles provide improved delivery of VIP and allow for acute treatment and optionally for sustained release of VIP in a patient.
    Type: Application
    Filed: June 15, 2016
    Publication date: February 23, 2017
    Applicant: AVANT GARDE THERAPEUTICS AND TECHNOLOGIES, LLC
    Inventors: Leo RUBIN, Shaker MOUSA
  • Patent number: 9381255
    Abstract: Nanoparticles comprising T3 and their use in treating, e.g., cardiac conditions, for example cardiac arrest, are provided. Such nanoparticles provide improved delivery of T3 and allow for acute treatment and optionally for sustained release of T3 in a patient.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: July 5, 2016
    Assignee: AVANT GARDE THERAPEUTICS AND TECHNOLOGIES LLC
    Inventors: Leo Rubin, Shaker Mousa
  • Publication number: 20160151532
    Abstract: Disclosed herein is a novel hemostatic patch that may be used to control and/or arrest bleeding in patients. The patch offers an effective but also minimally invasive way to control and/or arrest bleeding in a patient. The patch comprises a mucoadhesive and a compound that causes vasoconstriction. In a preferred aspect, the patch comprises chitosan and Neuropeptide Y. Also disclosed are methods of using the novel hemostatic patch.
    Type: Application
    Filed: November 23, 2015
    Publication date: June 2, 2016
    Inventors: Leo RUBIN, Shaker MOUSA
  • Patent number: 9216239
    Abstract: The present invention relates to intra-lumenal drug delivery devices. The device, such as a stent, is coated or impregnated with a pharmaceutical agent suitable for use in treatment of restenosis, pulmonary hypertension, and cancer. Suitable pharmaceutical agents include vasodilators and chemotherapeutics.
    Type: Grant
    Filed: February 10, 2005
    Date of Patent: December 22, 2015
    Inventor: Leo Rubin
  • Publication number: 20130337053
    Abstract: A formulation comprising T3/VIP nanoparticles, wherein the T3/VIP nanoparticle comprises both T3 and VIP encapsulated or immobilized on a bioabsorbable polymer. The invention further provides for methods of making a formulation comprising a T3/VIP nanoparticle. The invention further provides for methods of treatment utilizing said T3/VIP nanoparticle.
    Type: Application
    Filed: June 14, 2013
    Publication date: December 19, 2013
    Inventors: Leo RUBIN, Shaker MOUSA, Edward MATTES
  • Publication number: 20130338072
    Abstract: The present invention relates to methods of preventing or reducing the risk of acute and chronic rejection of transplanted organs. The invention relates to the administration of T3, VIP, and T3/VIP nanoparticles to a donor organ in order to prevent or reduce the risk of rejection, e.g. acute or chronic rejection.
    Type: Application
    Filed: June 14, 2013
    Publication date: December 19, 2013
    Inventors: Leo RUBIN, Shaker MOUSA
  • Publication number: 20130243868
    Abstract: Nanoparticles comprising T3 and their use in treating, e.g., cardiac conditions, for example cardiac arrest, are provided. Such nanoparticles provide improved delivery of T3 and allow for acute treatment and optionally for sustained release of T3 in a patient.
    Type: Application
    Filed: February 26, 2013
    Publication date: September 19, 2013
    Applicant: Avant Garde Therapeutics and Technologies LLC
    Inventors: Leo RUBIN, Shaker Mousa
  • Patent number: 8404281
    Abstract: Nanoparticles comprising T3 and their use in treating, e.g., cardiac conditions, for example cardiac arrest, are provided. Such nanoparticles provide improved delivery of T3 and allow for acute treatment and optionally for sustained release of T3 in a patient.
    Type: Grant
    Filed: June 8, 2010
    Date of Patent: March 26, 2013
    Assignee: Avant Garde Therapeutics & Technologies LLC
    Inventors: Leo Rubin, Shaker Mousa
  • Publication number: 20130041418
    Abstract: A method and device for discharging an electrical defibrillation pulse or an electrical demand pacer pulse or delivering at least one pharmaceutical agent to treat conditions such as cardiac arrest, bradycardia, arrhythmia, cardiac standstill, PEA, EMD and other heart conditions are disclosed. The pharmaceutical agent can be delivered into the heart tissue, the heart cavity, or the peritoneal cavity. The pharmaceutical agent can also include analgesics such as morphine. Also included are pharmaceutical agents used to increase myocardial contractility or inhibit platelet aggregation and vasoactive intestinal polypeptide (VIP) and thyroid hormones such as T3 and T4 can be delivered. A method for the treatment of cardiac arrest or pulmonary hypertension patients by administering a therapeutically effective amount of vasoactive intestinal polypeptide is also encompassed by the invention.
    Type: Application
    Filed: April 19, 2012
    Publication date: February 14, 2013
    Inventors: Leo Rubin, David Bernstein
  • Patent number: 8183203
    Abstract: A method and device for discharging an electrical defibrillation pulse or an electrical demand pacer pulse or delivering at least one pharmaceutical agent to treat conditions such as cardiac arrest, bradycardia, arrhythmia, cardiac standstill, PEA, EMD and other heart conditions are disclosed. The pharmaceutical agent can be delivered into the heart tissue, the heart cavity, or the peritoneal cavity. The pharmaceutical agent can also include analgesics such as morphine. Also included are pharmaceutical agents used to increase myocardial contractility or inhibit platelet aggregation and vasoactive intestinal polypeptide (VIP) and thyroid hormones such as T3 and T4 can be delivered. A method for the treatment of cardiac arrest or pulmonary hypertension patients by administering a therapeutically effective amount of vasoactive intestinal polypeptide is also encompassed by the invention.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: May 22, 2012
    Assignee: Avant Garde Therapeutics & Technologies LLC
    Inventor: Leo Rubin
  • Patent number: 8145303
    Abstract: Methods and apparatus for treating fibrillation utilize biphasic waveforms. A cardiac stimulator includes a defibrillation circuit that uses a pulse width modulated capacitive discharge to generate various biphasic waveforms, one or more of which may be delivered to the heart to treat the fibrillation.
    Type: Grant
    Filed: February 17, 2011
    Date of Patent: March 27, 2012
    Assignee: Intermedics Inc.
    Inventors: Leo Rubin, Chris A. Bonnerup, Edward A. Schroeppel
  • Publication number: 20110144706
    Abstract: Methods and apparatus for treating fibrillation utilize biphasic waveforms. A cardiac stimulator includes a defibrillation circuit that uses a pulse width modulated capacitive discharge to generate various biphasic waveforms, one or more of which may be delivered to the heart to treat the fibrillation.
    Type: Application
    Filed: February 17, 2011
    Publication date: June 16, 2011
    Inventors: Leo Rubin, Chris A. Bonnerup, Edward A. Schroeppel
  • Publication number: 20110142947
    Abstract: Nanoparticles comprising T3 and their use in treating, e.g., cardiac conditions, for example cardiac arrest, are provided. Such nanoparticles provide improved delivery of T3 and allow for acute treatment and optionally for sustained release of T3 in a patient.
    Type: Application
    Filed: June 8, 2010
    Publication date: June 16, 2011
    Inventors: Leo Rubin, Shaker Mousa
  • Patent number: 7899530
    Abstract: Methods and apparatus for treating fibrillation utilize biphasic waveforms. A cardiac stimulator includes a defibrillation circuit that uses a pulse width modulated capacitive discharge to generate various biphasic waveforms, one or more of which may be delivered to the heart to treat the fibrillation.
    Type: Grant
    Filed: February 21, 2008
    Date of Patent: March 1, 2011
    Assignee: Intermedics Inc.
    Inventors: Leo Rubin, Chris A. Bonnerup, Edward A. Schroeppel
  • Publication number: 20100161038
    Abstract: The present invention relates to intra-lumenal drug delivery devices. The device, such as a stent, is coated or impregnated with a pharmaceutical agent suitable for use in treatment of restenosis, pulmonary hypertension, and cancer. Suitable pharmaceutical agents include vasodilators and chemotherapeutics.
    Type: Application
    Filed: February 10, 2005
    Publication date: June 24, 2010
    Inventor: Leo Rubin
  • Publication number: 20100016212
    Abstract: A method and device for discharging an electrical defibrillation pulse or an electrical demand pacer pulse or delivering at least one pharmaceutical agent to treat conditions such as cardiac arrest bradycardia, arrhythmia, cardiac standstill, PEA, EMD and other heart conditions are disclosed. The pharmaceutical agent can be delivered into the heart tissue, the heart cavity. or the peritoneal cavity. The pharmaceutical agent can also include analgesics such as morphine. Also included are pharmaceutical agents used to increase myocardial contractility or inhibit platelet aggregation and vasoactive intestinal polypeptide (VIP) and thyroid hormones such as T3 and T4 can he delivered. A method for the treatment of cardiac arrest or pulmonary hypenension patients by administering a therapeutically effective amount of vasoactive intestinal polypeptide is also encompassed by the invention.
    Type: Application
    Filed: September 25, 2009
    Publication date: January 21, 2010
    Inventors: Leo Rubin, David Bernstein
  • Publication number: 20080147134
    Abstract: Methods and apparatus for treating fibrillation utilize biphasic waveforms. A cardiac stimulator includes a defibrillation circuit that uses a pulse width modulated capacitive discharge to generate various biphasic waveforms, one or more of which may be delivered to the heart to treat the fibrillation.
    Type: Application
    Filed: February 21, 2008
    Publication date: June 19, 2008
    Inventors: Leo Rubin, Christopher A. Bonnerup, Edward A. Schroeppel
  • Patent number: 7349735
    Abstract: Methods and apparatus for treating fibrillation utilize biphasic waveforms. A cardiac stimulator includes a defibrillation circuit that uses a pulse width modulated capacitive discharge to generate various biphasic waveforms, one or more of which may be delivered to the heart to treat the fibrillation.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: March 25, 2008
    Assignee: Intermedics Inc.
    Inventors: Leo Rubin, Christopher A. Bonnerup, Edward A. Schroeppel
  • Publication number: 20080051882
    Abstract: The present invention relates to intra-lumenal drug delivery devices. The device, such as a stent, is coated or impregnated with a pharmaceutical agent suitable for use in treatment of restenosis, pulmonary hypertension, and cancer. Suitable pharmaceutical agents include vasodilators and chemotherapeutics.
    Type: Application
    Filed: February 10, 2005
    Publication date: February 28, 2008
    Inventor: Leo Rubin